Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | NQO2 | P16083 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 2/20 | 0.47 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36846569 | 1.00 | ABL1 (0.64) | ABL1CYP3A4GAANQO2KDM4E | |
| SCHEMBL505256 | 0.85 | ABL1 (0.64) | ABL1CYP3A4GAANQO2KDM4E | |
| SCHEMBL31636576 | 0.84 | ABL1 (0.62) | ABL1CYP3A4GAANQO2KDM4E | |
| SCHEMBL1549467 | 0.84 | ABL1 (0.62) | ABL1CYP3A4GAANQO2KDM4E | |
| SCHEMBL28665944 | 0.84 | KDM4E (0.59) | ABL1CYP3A4GAANQO2KDM4E | |
| SCHEMBL25612414 | 0.84 | ABL1 (0.53) | ABL1CYP3A4GAANQO2KDM4E | |
| SCHEMBL12499408 | 0.84 | ABL1 (0.62) | ABL1CYP3A4GAANQO2KDM4E | |
| SCHEMBL1461725 | 0.82 | ABL1 (0.60) | ABL1CYP3A4GAANQO2KDM4E | |
| SCHEMBL13280615 | 0.82 | ABL1 (0.60) | ABL1CYP3A4GAANQO2KDM4E | |
| SCHEMBL13280732 | 0.82 | ABL1 (0.60) | ABL1CYP3A4GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337017-A1 | HERBICIDE/SAFENER COMBINATION BASED ON SAFENERS FROM THE CLASS OF SUBSTITUTED [(1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL)OXY]ACETIC ACIDS AND THEIR SALTS | Bayer Aktiengesellschaft (DE) | 2024-03-20 | — | — | EP | claimed |
| WO-2022152728-A1 | HERBICIDAL COMPOSITIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-21 | — | — | WO | claimed |
| EP-4719606-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260049039-A1 | MICROFIBRILLATED CELLULOSE AS RHEOLOGY MODIFIER IN HIGH IONIC STRENGTH AGRICULTURAL FORMULATIONS | AMVAC CHEMICAL CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250281926-A1 | SAMPLE MANIPULATION AND ASSAY WITH RAPID TEMPERATURE CHANGE | ESSENLIX CORPORATION (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4605378-A2 | BROMINE- OR IODINE-PARA-SUBSTITUTED [(1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL)OXY]ACETIC ACID DERIVATIVES AND THEIR SALTS, AGENTS FOR PROTECTING USEFUL PLANTS OR CROP PLANTS COMPRISING THEM, METHODS FOR PRODUCING THEM AND THEIR USE AS SAFENERS | Bayer Aktiengesellschaft (DE) | 2025-08-27 | — | — | EP | disclosed |
| US-12378165-B2 | Pesticide formulation comprising MFC as rheology modifier | AMVAC CHEMICAL CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250128993-A1 | AGRICULTURAL ADJUVANT COMPRISING MICROFIBRILLATED CELLULOSE | AMVAC CHEMICAL CORPORATION | 2025-04-24 | — | — | US | disclosed |
| US-20250099965-A1 | RAPID SAMPLE TEMPERATURE CHANGING FOR ASSAYING | ESSENLIX CORPORATION (US) | 2025-03-27 | — | — | US | disclosed |
| US-12226769-B2 | Sample manipulation and assay with rapid temperature change | ESSENLIX CORPORATION (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2024249493-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-12-07 | — | — | US | disclosed |
| EP-1724268-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1041980-B1 | ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-6011059-A | PREVENTING OR TREATING ANGINA PECTORIS, CARDIAC DYSFUNCTION, MYOCARDIAL NECROSIS, AND ARRHYTHMIA EMPLOYING THE ABOVE ACYL GUANIDINES. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| US-4344857-A | Encapsulation by entrapment | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1982-08-17 | — | — | US | disclosed |
| US-4104049-A | Chlorine-substituted vinylaminobenzoic acid compounds and plant growth regulant compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049039-A1 | MICROFIBRILLATED CELLULOSE AS RHEOLOGY MODIFIER IN HIGH IONIC STRENGTH AGRICULTURAL FORMULATIONS | FIBP, GHDC, MASTL | ABL1 2629/4885CYP3A4 4392/4885GAA 2440/4885 |
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | ENPP1, ENPP3, SMPD1 | ABL1 555/4885CYP3A4 2428/4885GAA 111/4885 |
| US-12378165-B2 | Pesticide formulation comprising MFC as rheology modifier | MFAP1, PFAS, DDT | ABL1 4877/4885CYP3A4 774/4885GAA 3472/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | ABL1 2333/4885CYP3A4 1724/4885GAA 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.